1
|
Parsaei M, Sheipouri A, Partovifar P, Shahriarinamin M, Sani SM, Taebi M, Arvin A. Diffusion magnetic resonance imaging for treatment response prediction in schizophrenia spectrum disorders: A systematic review. Psychiatry Res Neuroimaging 2024; 342:111841. [PMID: 38870842 DOI: 10.1016/j.pscychresns.2024.111841] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/02/2024] [Revised: 05/11/2024] [Accepted: 06/04/2024] [Indexed: 06/15/2024]
Abstract
A substantial portion of schizophrenia spectrum disorder (SSD) patients exhibit resistance to antipsychotic treatments, emphasizing the need for reliable treatment response biomarkers. Previous magnetic resonance imaging (MRI) studies have identified various imaging predictors in SSD. This study focuses on evaluating the effectiveness of diffusion MRI sequences, diffusion tensor imaging (DTI) and diffusion-weighted imaging (DWI), in predicting antipsychotic response in SSD patients. A systematic search for relevant articles was conducted in PubMed, Embase, Scopus, and Web of Science on February 11, 2024. Twelve studies involving a total of 742 patients were systematically reviewed. The baseline DTI/DWI biomarkers revealed significant associations with antipsychotic treatment response. Notably a consistent negative link was found between response and baseline fractional anisotropy (FA) in fronto-temporo-limbic white matter tracts, specifically the superior longitudinal fasciculus, providing moderate-level evidence. In addition, weak-level evidence was found for the negative association between the treatment response and baseline FA in the corpus callosum, internal, and external capsule tracts. Collectively, this review demonstrated that obtaining pre-treatment brain diffusion MRI scans, particularly from white matter tracts of fronto-temporo-limbic network, can assist in delineating the treatment response trajectory in patients with SSD. However, additional larger randomized controlled trials are required to further substantiate these findings.
Collapse
Affiliation(s)
- Mohammadamin Parsaei
- Breastfeeding Research Center, Family Health Research Institute, Tehran University of Medical Sciences, Tehran, Iran; Maternal, Fetal & Neonatal Research Center, Family Health Research Institute, Tehran University of Medical Sciences, Tehran, Iran.
| | - Amirmahdi Sheipouri
- NCweb Association, Students' Scientific Research Center (SSRC), Tehran University of Medical Sciences, Tehran, Iran; Neuroscience Research Center, Kerman University of Medical Sciences, Kerman, Iran
| | - Paniz Partovifar
- Maternal, Fetal & Neonatal Research Center, Family Health Research Institute, Tehran University of Medical Sciences, Tehran, Iran; Iranian Center of Neurological Research, Tehran University of Medical Sciences, Tehran, Iran
| | - Maryam Shahriarinamin
- NCweb Association, Students' Scientific Research Center (SSRC), Tehran University of Medical Sciences, Tehran, Iran; Department of Neuroscience, School of Medicine, Guilan University of Medical Sciences, Rasht, Iran
| | - Sheida Mobader Sani
- NCweb Association, Students' Scientific Research Center (SSRC), Tehran University of Medical Sciences, Tehran, Iran; Iranian Center of Neurological Research, Tehran University of Medical Sciences, Tehran, Iran
| | - Morvarid Taebi
- Center for Orthopedic Trans-Disciplinary Applied Research, Tehran University of Medical Sciences, Tehran, Iran
| | - Alireza Arvin
- Center for Orthopedic Trans-Disciplinary Applied Research, Tehran University of Medical Sciences, Tehran, Iran
| |
Collapse
|
2
|
León-Ortiz P, Reyes-Madrigal F, Kochunov P, Gómez-Cruz G, Moncada-Habib T, Malacara M, Mora-Durán R, Rowland LM, de la Fuente-Sandoval C. White matter alterations and the conversion to psychosis: A combined diffusion tensor imaging and glutamate 1H MRS study. Schizophr Res 2022; 249:85-92. [PMID: 32595100 PMCID: PMC10025976 DOI: 10.1016/j.schres.2020.06.006] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/27/2020] [Revised: 06/08/2020] [Accepted: 06/10/2020] [Indexed: 12/14/2022]
Abstract
INTRODUCTION Widespread white matter abnormalities and alterations in glutamate levels have been reported in patients with schizophrenia. We hypothesized that alterations in white matter integrity and glutamate levels in individuals at clinical high risk (CHR) for psychosis are associated with the subsequent development of psychosis. METHODS Participants included 33 antipsychotic naïve CHR (Female 7/Male 26, Age 19.55 (4.14) years) and 38 healthy controls (Female 10/Male 28, Age 20.92 (3.37) years). Whole brain diffusion tensor imaging for fractional anisotropy (FA) and right frontal white matter proton magnetic resonance spectroscopy for glutamate levels were acquired. CHR participants were clinically followed for 2 years to determine conversion to psychosis. RESULTS CHR participants that transitioned to psychosis (N = 7, 21%) were characterized by significantly lower FA values in the posterior thalamic radiation compared to those who did not transition and healthy controls. In the CHR group that transitioned to psychosis only, positive exploratory correlations between glutamate levels and FA values of the posterior thalamic radiation and the retrolenticular part of the internal capsule and a negative correlation between glutamate levels and the cingulum FA values were found. CONCLUSION The results of the present study highlight that alterations in white matter structure and glutamate are related with the conversion to psychosis.
Collapse
Affiliation(s)
- Pablo León-Ortiz
- Laboratory of Experimental Psychiatry, Instituto Nacional de Neurología y Neurocirugía, Mexico City, Mexico; Department of Education, Instituto Nacional de Neurología y Neurocirugía, Mexico City, Mexico
| | - Francisco Reyes-Madrigal
- Laboratory of Experimental Psychiatry, Instituto Nacional de Neurología y Neurocirugía, Mexico City, Mexico
| | - Peter Kochunov
- Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, United States of America
| | - Gladys Gómez-Cruz
- Laboratory of Experimental Psychiatry, Instituto Nacional de Neurología y Neurocirugía, Mexico City, Mexico
| | - Tomás Moncada-Habib
- Laboratory of Experimental Psychiatry, Instituto Nacional de Neurología y Neurocirugía, Mexico City, Mexico
| | - Melanie Malacara
- Laboratory of Experimental Psychiatry, Instituto Nacional de Neurología y Neurocirugía, Mexico City, Mexico
| | - Ricardo Mora-Durán
- Emergency Department, Hospital Fray Bernardino Álvarez, Mexico City, Mexico
| | - Laura M Rowland
- Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, United States of America
| | - Camilo de la Fuente-Sandoval
- Laboratory of Experimental Psychiatry, Instituto Nacional de Neurología y Neurocirugía, Mexico City, Mexico; Neuropsychiatry Department, Instituto Nacional de Neurología y Neurocirugía, Mexico City, Mexico.
| |
Collapse
|
3
|
Prats C, Fatjó-Vilas M, Penzol MJ, Kebir O, Pina-Camacho L, Demontis D, Crespo-Facorro B, Peralta V, González-Pinto A, Pomarol-Clotet E, Papiol S, Parellada M, Krebs MO, Fañanás L. Association and epistatic analysis of white matter related genes across the continuum schizophrenia and autism spectrum disorders: The joint effect of NRG1-ErbB genes. World J Biol Psychiatry 2022; 23:208-218. [PMID: 34338147 DOI: 10.1080/15622975.2021.1939155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
Abstract
BACKGROUND Schizophrenia-spectrum disorders (SSD) and Autism spectrum disorders (ASD) are neurodevelopmental disorders that share clinical, cognitive, and genetic characteristics, as well as particular white matter (WM) abnormalities. In this study, we aimed to investigate the role of a set of oligodendrocyte/myelin-related (OMR) genes and their epistatic effect on the risk for SSD and ASD. METHODS We examined 108 SNPs in a set of 22 OMR genes in 1749 subjects divided into three independent samples (187 SSD trios, 915 SSD cases/control, and 91 ASD trios). Genetic association and gene-gene interaction analyses were conducted with PLINK and MB-MDR, and permutation procedures were implemented in both. RESULTS Some OMR genes showed an association trend with SSD, while after correction, the ones that remained significantly associated were MBP, ERBB3, and AKT1. Significant gene-gene interactions were found between (i) NRG1*MBP (perm p-value = 0.002) in the SSD trios sample, (ii) ERBB3*AKT1 (perm p-value = 0.001) in the SSD case-control sample, and (iii) ERBB3*QKI (perm p-value = 0.0006) in the ASD trios sample. DISCUSSION Our results suggest the implication of OMR genes in the risk for both SSD and ASD and highlight the role of NRG1 and ERBB genes. These findings are in line with the previous evidence and may suggest pathophysiological mechanisms related to NRG1/ERBBs signalling in these disorders.
Collapse
Affiliation(s)
- C Prats
- Departament de Biologia Evolutiva, Ecologia i Ciències Ambientals, Facultat de Biologia, Universitat de Barcelona, Spain; Institut de Biomedicina de la Universitat de Barcelona (IBUB), Barcelona, Spain.,Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain.,Institut d'Investigació Biomèdica de Bellvitge, Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona, Spain
| | - M Fatjó-Vilas
- Departament de Biologia Evolutiva, Ecologia i Ciències Ambientals, Facultat de Biologia, Universitat de Barcelona, Spain; Institut de Biomedicina de la Universitat de Barcelona (IBUB), Barcelona, Spain.,Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain.,FIDMAG Germanes Hospitalàries Research Foundation, Barcelona, Spain
| | - M J Penzol
- Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain.,Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, IiSGM, Madrid, Spain
| | - O Kebir
- INSERM, U1266, Laboratory "Pathophysiology of psychiatric disorders", Institute of psychiatry and neurosciences of Paris, Paris, France.,GHU Psychiatrie et Neurosciences de Paris, Paris, France
| | - L Pina-Camacho
- Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain.,Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, IiSGM, Madrid, Spain
| | - D Demontis
- Department of Biomedicine, Aarhus University, Aarhus, Denmark; The Lundbeck Foundation Initiative for Integrative Psychiatric Research iPSYCH, Aarhus, Denmark
| | - B Crespo-Facorro
- Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain.,University Hospital Virgen del Rocio, IbiS Department of Psychiatry, School of Medicine, University of Sevilla, Sevilla, Spain
| | - V Peralta
- Gerencia de Salud Mental, Servicio Navarro de Salud-Osasunbidea, Pamplona, Navarra, Spain.,Instituto de Investigación Sanitaria de Navarra (IdiSNa), Pamplona, Navarra, Spain
| | - A González-Pinto
- Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain.,Psychiatry Service, University Hospital of Alava-Santiago, EMBREC, EHU/UPV University of the Basque Country, Kronikgune, Vitoria, Spain
| | - E Pomarol-Clotet
- Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain.,FIDMAG Germanes Hospitalàries Research Foundation, Barcelona, Spain
| | - S Papiol
- Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain.,Institute of Psychiatric Phenomics and Genomics (IPPG), University Hospital, LMU Munich, Munich, Germany.,Department of Psychiatry, University Hospital, Ludwig Maximilian University, Munich, Germany
| | - M Parellada
- Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain.,Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, School of Medicine, Universidad Complutense, IiSGM, Madrid, Spain
| | - M O Krebs
- INSERM, U1266, Laboratory "Pathophysiology of psychiatric disorders", Institute of psychiatry and neurosciences of Paris, Paris, France.,University Paris Descartes, Sorbonne Paris Cité, Faculté de Médecine Paris Descartes, Service Hospitalo-Universitaire, Centre Hospitalier Sainte-Anne, Paris, France
| | - L Fañanás
- Departament de Biologia Evolutiva, Ecologia i Ciències Ambientals, Facultat de Biologia, Universitat de Barcelona, Spain; Institut de Biomedicina de la Universitat de Barcelona (IBUB), Barcelona, Spain.,Instituto de Salud Carlos III, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid, Spain
| |
Collapse
|
4
|
Barettino C, Ballesteros-Gonzalez Á, Aylón A, Soler-Sanchis X, Ortí L, Díaz S, Reillo I, García-García F, Iborra FJ, Lai C, Dehorter N, Leinekugel X, Flames N, Del Pino I. Developmental Disruption of Erbb4 in Pet1+ Neurons Impairs Serotonergic Sub-System Connectivity and Memory Formation. Front Cell Dev Biol 2021; 9:770458. [PMID: 34957103 PMCID: PMC8703035 DOI: 10.3389/fcell.2021.770458] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/03/2021] [Accepted: 11/19/2021] [Indexed: 11/30/2022] Open
Abstract
The serotonergic system of mammals innervates virtually all the central nervous system and regulates a broad spectrum of behavioral and physiological functions. In mammals, serotonergic neurons located in the rostral raphe nuclei encompass diverse sub-systems characterized by specific circuitry and functional features. Substantial evidence suggest that functional diversity of serotonergic circuits has a molecular and connectivity basis. However, the landscape of intrinsic developmental mechanisms guiding the formation of serotonergic sub-systems is unclear. Here, we employed developmental disruption of gene expression specific to serotonergic subsets to probe the contribution of the tyrosine kinase receptor ErbB4 to serotonergic circuit formation and function. Through an in vivo loss-of-function approach, we found that ErbB4 expression occurring in a subset of serotonergic neurons, is necessary for axonal arborization of defined long-range projections to the forebrain but is dispensable for the innervation of other targets of the serotonergic system. We also found that Erbb4-deletion does not change the global excitability or the number of neurons with serotonin content in the dorsal raphe nuclei. In addition, ErbB4-deficiency in serotonergic neurons leads to specific behavioral deficits in memory processing that involve aversive or social components. Altogether, our work unveils a developmental mechanism intrinsically acting through ErbB4 in subsets of serotonergic neurons to orchestrate a precise long-range circuit and ultimately involved in the formation of emotional and social memories.
Collapse
Affiliation(s)
- Candela Barettino
- Neural Plasticity Laboratory, Príncipe Felipe Research Center, Valencia, Spain
| | | | - Andrés Aylón
- Neural Plasticity Laboratory, Príncipe Felipe Research Center, Valencia, Spain
| | | | - Leticia Ortí
- Neural Plasticity Laboratory, Príncipe Felipe Research Center, Valencia, Spain
| | - Selene Díaz
- Neural Plasticity Laboratory, Príncipe Felipe Research Center, Valencia, Spain
| | - Isabel Reillo
- Developmental Neurobiology Unit, Instituto de Biomedicina de Valencia, IBV-CSIC, Valencia, Spain
| | - Francisco García-García
- Bioinformatics and Biostatistics Unit, Príncipe Felipe Research Center (CIPF), Valencia, Spain
| | | | - Cary Lai
- Department of Psychological and Brain Sciences, Indiana University, Bloomington, IN, United States
| | | | - Xavier Leinekugel
- Institut de Neurobiology de la Méditerranée (INMED, UMR1249), INSERM, Marseille, France
| | - Nuria Flames
- Developmental Neurobiology Unit, Instituto de Biomedicina de Valencia, IBV-CSIC, Valencia, Spain
| | - Isabel Del Pino
- Neural Plasticity Laboratory, Príncipe Felipe Research Center, Valencia, Spain
| |
Collapse
|
5
|
Jahn K, Heese A, Kebir O, Groh A, Bleich S, Krebs MO, Frieling H. Differential Methylation Pattern of Schizophrenia Candidate Genes in Tetrahydrocannabinol-Consuming Treatment-Resistant Schizophrenic Patients Compared to Non-Consumer Patients and Healthy Controls. Neuropsychobiology 2021; 80:36-44. [PMID: 32599581 DOI: 10.1159/000507670] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/07/2019] [Accepted: 04/02/2020] [Indexed: 11/19/2022]
Abstract
BACKGROUND Patients suffering from schizophrenic psychosis show reduced synaptic connectivity compared to healthy individuals. Furthermore, the use of cannabis often precedes the onset of schizophrenic psychosis. Therefore, we investigated whether consumption of cannabis has an impact on the methylation pattern of schizophrenia candidate genes concerned with the development and preservation of synapses and synaptic function. METHODS Fifty blood samples of outpatients affected by treatment-resistant schizophrenic psychosis were collected in the outpatient department of Ch Ste Anne/INSERM (Paris, France). Extracted DNA was sent to the LMN/MHH (Hanover, Germany) where DNA samples were bisulfite converted. The methylation patterns of the promoter region of neuregulin 1 (NRG1), neurexin (NRXN1), disrupted in schizophrenia 1 (DISC1), and microtubule-associated-protein tau (MAPT) were then analysed by sequencing according to Sanger. RESULTS In NRXN1 the group of non-consumer patients showed a methylation rate slightly lower than controls. In patients with preliminary use of tetrahydrocannabinol (THC) the NRXN1 promoter turned out to be methylated almost two times higher than in non-consumer patients. In MAPT, non-consumer patients showed a significant lower mean methylation rate in comparison to controls. In THC-consuming patients the difference compared with controls became less. NRG1 and DISC1 showed no significant differences between groups, whereas DISC1 appeared to be not methylated at all. CONCLUSION In MAPT and NRXN1 mean methylation rates were lower in non-consumer patients compared with controls, which seems to be a compensatory mechanism. With consumption of THC, mean methylation rates were increased: in the case of MAPT compared with controls, and in NRXN1 even significantly beyond that. Methylation of NRG1 and DISC1 seems not to be affected by the psychiatric disorder or by consumption of THC.
Collapse
Affiliation(s)
- Kirsten Jahn
- Laboratory for Molecular Neurosciences (LMN), Department of Psychiatry, Social Psychiatry and Psychotherapy, Medical School Hannover (MHH), Hannover, Germany,
| | - Astrid Heese
- Laboratory for Molecular Neurosciences (LMN), Department of Psychiatry, Social Psychiatry and Psychotherapy, Medical School Hannover (MHH), Hannover, Germany
| | - Oussama Kebir
- Centre Hospitalier Sainte Anne (Ch Ste Anne), Paris, France
| | - Adrian Groh
- Laboratory for Molecular Neurosciences (LMN), Department of Psychiatry, Social Psychiatry and Psychotherapy, Medical School Hannover (MHH), Hannover, Germany
| | - Stefan Bleich
- Laboratory for Molecular Neurosciences (LMN), Department of Psychiatry, Social Psychiatry and Psychotherapy, Medical School Hannover (MHH), Hannover, Germany
| | | | - Helge Frieling
- Laboratory for Molecular Neurosciences (LMN), Department of Psychiatry, Social Psychiatry and Psychotherapy, Medical School Hannover (MHH), Hannover, Germany
| |
Collapse
|
6
|
Duan J, Wei Y, Womer FY, Zhang X, Chang M, Zhu Y, Liu Z, Li C, Yin Z, Zhang R, Sun J, Wang P, Wang S, Jiang X, Wei S, Zhang Y, Tang Y, Wang F. Neurobiological substrates of major psychiatry disorders: transdiagnostic associations between white matter abnormalities, neuregulin 1 and clinical manifestation. J Psychiatry Neurosci 2021; 46:E506-E515. [PMID: 34467747 PMCID: PMC8526153 DOI: 10.1503/jpn.200166] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
Abstract
BACKGROUND Schizophrenia, bipolar disorder and major depressive disorder are increasingly being conceptualized as a transdiagnostic continuum. Disruption of white matter is a common alteration in these psychiatric disorders, but the molecular mechanisms underlying the disruption remain unclear. Neuregulin 1 (NRG1) is genetically linked with susceptibility to schizophrenia, bipolar disorder and major depressive disorder, and it is also related to white matter. METHODS Using a transdiagnostic approach, we aimed to identify white matter differences associated with NRG1 and their relationship to transdiagnostic symptoms and cognitive function. We examined the white matter of 1051 participants (318 healthy controls and 733 patients with major psychiatric disorders: 254 with schizophrenia, 212 with bipolar disorder and 267 with major depressive disorder) who underwent diffusion tensor imaging. We measured the plasma NRG1-β1 levels of 331 participants. We also evaluated clinical symptoms and cognitive function. RESULTS In the patient group, abnormal white matter was negatively associated with NRG1-β1 levels in the genu of the corpus callosum, right uncinate fasciculus, bilateral inferior fronto-occipital fasciculus, right external capsule, fornix, right optic tract, left straight gyrus white matter and left olfactory radiation. These NRG1-associated white matter abnormalities were also associated with depression and anxiety symptoms and executive function in patients with a major psychiatric disorder. Furthermore, across the 3 disorders we observed analogous alterations in white matter, NRG1-β1 levels and clinical manifestations. LIMITATIONS Medication status, the wide age range and our cross-sectional findings were limitations of this study. CONCLUSION This study is the first to provide evidence for an association between NRG1, white matter abnormalities, clinical symptoms and cognition in a transdiagnostic psychiatric cohort. These findings provide further support for an understanding of the molecular mechanisms that underlie the neuroimaging substrates of major psychiatric disorders and their clinical implications.
Collapse
Affiliation(s)
- Jia Duan
- From the Department of Psychiatry, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Duan, Zhu, Yin, R. Zhang, Sun, P. Wang, S. Wang, Tang, F. Wang); the Early Intervention Unit, Department of Psychiatry, Affiliated Nanjing Brain Hospital, Nanjing Medical University, Nanjing, PR China (Duan, Y. Wei, R. Zhang, F. Wang); the Department of Psychiatry and Behavioral Neuroscience, Saint Louis University, St. Louis, MO (Womer); the School of Biomedical Engineering and Informatics, Nanjing Medical University, Nanjing, Jiangsu, PR China (X. Zhang); the Department of Radiology, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Chang, Li, Jiang, S.Wei); the School of Public Health, China Medical University, Shenyang, Liaoning, PR China (Liu); the Department of Psychiatry, College of Medicine, University of Saskatchewan, SK (Y. Zhang)
| | - Yange Wei
- From the Department of Psychiatry, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Duan, Zhu, Yin, R. Zhang, Sun, P. Wang, S. Wang, Tang, F. Wang); the Early Intervention Unit, Department of Psychiatry, Affiliated Nanjing Brain Hospital, Nanjing Medical University, Nanjing, PR China (Duan, Y. Wei, R. Zhang, F. Wang); the Department of Psychiatry and Behavioral Neuroscience, Saint Louis University, St. Louis, MO (Womer); the School of Biomedical Engineering and Informatics, Nanjing Medical University, Nanjing, Jiangsu, PR China (X. Zhang); the Department of Radiology, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Chang, Li, Jiang, S.Wei); the School of Public Health, China Medical University, Shenyang, Liaoning, PR China (Liu); the Department of Psychiatry, College of Medicine, University of Saskatchewan, SK (Y. Zhang)
| | - Fay Y Womer
- From the Department of Psychiatry, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Duan, Zhu, Yin, R. Zhang, Sun, P. Wang, S. Wang, Tang, F. Wang); the Early Intervention Unit, Department of Psychiatry, Affiliated Nanjing Brain Hospital, Nanjing Medical University, Nanjing, PR China (Duan, Y. Wei, R. Zhang, F. Wang); the Department of Psychiatry and Behavioral Neuroscience, Saint Louis University, St. Louis, MO (Womer); the School of Biomedical Engineering and Informatics, Nanjing Medical University, Nanjing, Jiangsu, PR China (X. Zhang); the Department of Radiology, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Chang, Li, Jiang, S.Wei); the School of Public Health, China Medical University, Shenyang, Liaoning, PR China (Liu); the Department of Psychiatry, College of Medicine, University of Saskatchewan, SK (Y. Zhang)
| | - Xizhe Zhang
- From the Department of Psychiatry, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Duan, Zhu, Yin, R. Zhang, Sun, P. Wang, S. Wang, Tang, F. Wang); the Early Intervention Unit, Department of Psychiatry, Affiliated Nanjing Brain Hospital, Nanjing Medical University, Nanjing, PR China (Duan, Y. Wei, R. Zhang, F. Wang); the Department of Psychiatry and Behavioral Neuroscience, Saint Louis University, St. Louis, MO (Womer); the School of Biomedical Engineering and Informatics, Nanjing Medical University, Nanjing, Jiangsu, PR China (X. Zhang); the Department of Radiology, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Chang, Li, Jiang, S.Wei); the School of Public Health, China Medical University, Shenyang, Liaoning, PR China (Liu); the Department of Psychiatry, College of Medicine, University of Saskatchewan, SK (Y. Zhang)
| | - Miao Chang
- From the Department of Psychiatry, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Duan, Zhu, Yin, R. Zhang, Sun, P. Wang, S. Wang, Tang, F. Wang); the Early Intervention Unit, Department of Psychiatry, Affiliated Nanjing Brain Hospital, Nanjing Medical University, Nanjing, PR China (Duan, Y. Wei, R. Zhang, F. Wang); the Department of Psychiatry and Behavioral Neuroscience, Saint Louis University, St. Louis, MO (Womer); the School of Biomedical Engineering and Informatics, Nanjing Medical University, Nanjing, Jiangsu, PR China (X. Zhang); the Department of Radiology, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Chang, Li, Jiang, S.Wei); the School of Public Health, China Medical University, Shenyang, Liaoning, PR China (Liu); the Department of Psychiatry, College of Medicine, University of Saskatchewan, SK (Y. Zhang)
| | - Yue Zhu
- From the Department of Psychiatry, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Duan, Zhu, Yin, R. Zhang, Sun, P. Wang, S. Wang, Tang, F. Wang); the Early Intervention Unit, Department of Psychiatry, Affiliated Nanjing Brain Hospital, Nanjing Medical University, Nanjing, PR China (Duan, Y. Wei, R. Zhang, F. Wang); the Department of Psychiatry and Behavioral Neuroscience, Saint Louis University, St. Louis, MO (Womer); the School of Biomedical Engineering and Informatics, Nanjing Medical University, Nanjing, Jiangsu, PR China (X. Zhang); the Department of Radiology, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Chang, Li, Jiang, S.Wei); the School of Public Health, China Medical University, Shenyang, Liaoning, PR China (Liu); the Department of Psychiatry, College of Medicine, University of Saskatchewan, SK (Y. Zhang)
| | - Zhuang Liu
- From the Department of Psychiatry, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Duan, Zhu, Yin, R. Zhang, Sun, P. Wang, S. Wang, Tang, F. Wang); the Early Intervention Unit, Department of Psychiatry, Affiliated Nanjing Brain Hospital, Nanjing Medical University, Nanjing, PR China (Duan, Y. Wei, R. Zhang, F. Wang); the Department of Psychiatry and Behavioral Neuroscience, Saint Louis University, St. Louis, MO (Womer); the School of Biomedical Engineering and Informatics, Nanjing Medical University, Nanjing, Jiangsu, PR China (X. Zhang); the Department of Radiology, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Chang, Li, Jiang, S.Wei); the School of Public Health, China Medical University, Shenyang, Liaoning, PR China (Liu); the Department of Psychiatry, College of Medicine, University of Saskatchewan, SK (Y. Zhang)
| | - Chao Li
- From the Department of Psychiatry, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Duan, Zhu, Yin, R. Zhang, Sun, P. Wang, S. Wang, Tang, F. Wang); the Early Intervention Unit, Department of Psychiatry, Affiliated Nanjing Brain Hospital, Nanjing Medical University, Nanjing, PR China (Duan, Y. Wei, R. Zhang, F. Wang); the Department of Psychiatry and Behavioral Neuroscience, Saint Louis University, St. Louis, MO (Womer); the School of Biomedical Engineering and Informatics, Nanjing Medical University, Nanjing, Jiangsu, PR China (X. Zhang); the Department of Radiology, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Chang, Li, Jiang, S.Wei); the School of Public Health, China Medical University, Shenyang, Liaoning, PR China (Liu); the Department of Psychiatry, College of Medicine, University of Saskatchewan, SK (Y. Zhang)
| | - Zhiyang Yin
- From the Department of Psychiatry, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Duan, Zhu, Yin, R. Zhang, Sun, P. Wang, S. Wang, Tang, F. Wang); the Early Intervention Unit, Department of Psychiatry, Affiliated Nanjing Brain Hospital, Nanjing Medical University, Nanjing, PR China (Duan, Y. Wei, R. Zhang, F. Wang); the Department of Psychiatry and Behavioral Neuroscience, Saint Louis University, St. Louis, MO (Womer); the School of Biomedical Engineering and Informatics, Nanjing Medical University, Nanjing, Jiangsu, PR China (X. Zhang); the Department of Radiology, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Chang, Li, Jiang, S.Wei); the School of Public Health, China Medical University, Shenyang, Liaoning, PR China (Liu); the Department of Psychiatry, College of Medicine, University of Saskatchewan, SK (Y. Zhang)
| | - Ran Zhang
- From the Department of Psychiatry, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Duan, Zhu, Yin, R. Zhang, Sun, P. Wang, S. Wang, Tang, F. Wang); the Early Intervention Unit, Department of Psychiatry, Affiliated Nanjing Brain Hospital, Nanjing Medical University, Nanjing, PR China (Duan, Y. Wei, R. Zhang, F. Wang); the Department of Psychiatry and Behavioral Neuroscience, Saint Louis University, St. Louis, MO (Womer); the School of Biomedical Engineering and Informatics, Nanjing Medical University, Nanjing, Jiangsu, PR China (X. Zhang); the Department of Radiology, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Chang, Li, Jiang, S.Wei); the School of Public Health, China Medical University, Shenyang, Liaoning, PR China (Liu); the Department of Psychiatry, College of Medicine, University of Saskatchewan, SK (Y. Zhang)
| | - Jiaze Sun
- From the Department of Psychiatry, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Duan, Zhu, Yin, R. Zhang, Sun, P. Wang, S. Wang, Tang, F. Wang); the Early Intervention Unit, Department of Psychiatry, Affiliated Nanjing Brain Hospital, Nanjing Medical University, Nanjing, PR China (Duan, Y. Wei, R. Zhang, F. Wang); the Department of Psychiatry and Behavioral Neuroscience, Saint Louis University, St. Louis, MO (Womer); the School of Biomedical Engineering and Informatics, Nanjing Medical University, Nanjing, Jiangsu, PR China (X. Zhang); the Department of Radiology, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Chang, Li, Jiang, S.Wei); the School of Public Health, China Medical University, Shenyang, Liaoning, PR China (Liu); the Department of Psychiatry, College of Medicine, University of Saskatchewan, SK (Y. Zhang)
| | - Pengshuo Wang
- From the Department of Psychiatry, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Duan, Zhu, Yin, R. Zhang, Sun, P. Wang, S. Wang, Tang, F. Wang); the Early Intervention Unit, Department of Psychiatry, Affiliated Nanjing Brain Hospital, Nanjing Medical University, Nanjing, PR China (Duan, Y. Wei, R. Zhang, F. Wang); the Department of Psychiatry and Behavioral Neuroscience, Saint Louis University, St. Louis, MO (Womer); the School of Biomedical Engineering and Informatics, Nanjing Medical University, Nanjing, Jiangsu, PR China (X. Zhang); the Department of Radiology, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Chang, Li, Jiang, S.Wei); the School of Public Health, China Medical University, Shenyang, Liaoning, PR China (Liu); the Department of Psychiatry, College of Medicine, University of Saskatchewan, SK (Y. Zhang)
| | - Shuai Wang
- From the Department of Psychiatry, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Duan, Zhu, Yin, R. Zhang, Sun, P. Wang, S. Wang, Tang, F. Wang); the Early Intervention Unit, Department of Psychiatry, Affiliated Nanjing Brain Hospital, Nanjing Medical University, Nanjing, PR China (Duan, Y. Wei, R. Zhang, F. Wang); the Department of Psychiatry and Behavioral Neuroscience, Saint Louis University, St. Louis, MO (Womer); the School of Biomedical Engineering and Informatics, Nanjing Medical University, Nanjing, Jiangsu, PR China (X. Zhang); the Department of Radiology, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Chang, Li, Jiang, S.Wei); the School of Public Health, China Medical University, Shenyang, Liaoning, PR China (Liu); the Department of Psychiatry, College of Medicine, University of Saskatchewan, SK (Y. Zhang)
| | - Xiaowei Jiang
- From the Department of Psychiatry, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Duan, Zhu, Yin, R. Zhang, Sun, P. Wang, S. Wang, Tang, F. Wang); the Early Intervention Unit, Department of Psychiatry, Affiliated Nanjing Brain Hospital, Nanjing Medical University, Nanjing, PR China (Duan, Y. Wei, R. Zhang, F. Wang); the Department of Psychiatry and Behavioral Neuroscience, Saint Louis University, St. Louis, MO (Womer); the School of Biomedical Engineering and Informatics, Nanjing Medical University, Nanjing, Jiangsu, PR China (X. Zhang); the Department of Radiology, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Chang, Li, Jiang, S.Wei); the School of Public Health, China Medical University, Shenyang, Liaoning, PR China (Liu); the Department of Psychiatry, College of Medicine, University of Saskatchewan, SK (Y. Zhang)
| | - Shengnan Wei
- From the Department of Psychiatry, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Duan, Zhu, Yin, R. Zhang, Sun, P. Wang, S. Wang, Tang, F. Wang); the Early Intervention Unit, Department of Psychiatry, Affiliated Nanjing Brain Hospital, Nanjing Medical University, Nanjing, PR China (Duan, Y. Wei, R. Zhang, F. Wang); the Department of Psychiatry and Behavioral Neuroscience, Saint Louis University, St. Louis, MO (Womer); the School of Biomedical Engineering and Informatics, Nanjing Medical University, Nanjing, Jiangsu, PR China (X. Zhang); the Department of Radiology, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Chang, Li, Jiang, S.Wei); the School of Public Health, China Medical University, Shenyang, Liaoning, PR China (Liu); the Department of Psychiatry, College of Medicine, University of Saskatchewan, SK (Y. Zhang)
| | - Yanbo Zhang
- From the Department of Psychiatry, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Duan, Zhu, Yin, R. Zhang, Sun, P. Wang, S. Wang, Tang, F. Wang); the Early Intervention Unit, Department of Psychiatry, Affiliated Nanjing Brain Hospital, Nanjing Medical University, Nanjing, PR China (Duan, Y. Wei, R. Zhang, F. Wang); the Department of Psychiatry and Behavioral Neuroscience, Saint Louis University, St. Louis, MO (Womer); the School of Biomedical Engineering and Informatics, Nanjing Medical University, Nanjing, Jiangsu, PR China (X. Zhang); the Department of Radiology, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Chang, Li, Jiang, S.Wei); the School of Public Health, China Medical University, Shenyang, Liaoning, PR China (Liu); the Department of Psychiatry, College of Medicine, University of Saskatchewan, SK (Y. Zhang)
| | - Yanqing Tang
- From the Department of Psychiatry, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Duan, Zhu, Yin, R. Zhang, Sun, P. Wang, S. Wang, Tang, F. Wang); the Early Intervention Unit, Department of Psychiatry, Affiliated Nanjing Brain Hospital, Nanjing Medical University, Nanjing, PR China (Duan, Y. Wei, R. Zhang, F. Wang); the Department of Psychiatry and Behavioral Neuroscience, Saint Louis University, St. Louis, MO (Womer); the School of Biomedical Engineering and Informatics, Nanjing Medical University, Nanjing, Jiangsu, PR China (X. Zhang); the Department of Radiology, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Chang, Li, Jiang, S.Wei); the School of Public Health, China Medical University, Shenyang, Liaoning, PR China (Liu); the Department of Psychiatry, College of Medicine, University of Saskatchewan, SK (Y. Zhang)
| | - Fei Wang
- From the Department of Psychiatry, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Duan, Zhu, Yin, R. Zhang, Sun, P. Wang, S. Wang, Tang, F. Wang); the Early Intervention Unit, Department of Psychiatry, Affiliated Nanjing Brain Hospital, Nanjing Medical University, Nanjing, PR China (Duan, Y. Wei, R. Zhang, F. Wang); the Department of Psychiatry and Behavioral Neuroscience, Saint Louis University, St. Louis, MO (Womer); the School of Biomedical Engineering and Informatics, Nanjing Medical University, Nanjing, Jiangsu, PR China (X. Zhang); the Department of Radiology, First Affiliated Hospital of China Medical University, Shenyang, Liaoning, PR China (Chang, Li, Jiang, S.Wei); the School of Public Health, China Medical University, Shenyang, Liaoning, PR China (Liu); the Department of Psychiatry, College of Medicine, University of Saskatchewan, SK (Y. Zhang)
| |
Collapse
|
7
|
Götze T, Soto-Bernardini MC, Zhang M, Mießner H, Linhoff L, Brzózka MM, Velanac V, Dullin C, Ramos-Gomes F, Peng M, Husseini H, Schifferdecker E, Fledrich R, Sereda MW, Willig K, Alves F, Rossner MJ, Nave KA, Zhang W, Schwab MH. Hyperactivity is a Core Endophenotype of Elevated Neuregulin-1 Signaling in Embryonic Glutamatergic Networks. Schizophr Bull 2021; 47:1409-1420. [PMID: 33871014 PMCID: PMC8379540 DOI: 10.1093/schbul/sbab027] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/16/2023]
Abstract
The neuregulin 1 (NRG1) ErbB4 module is at the core of an "at risk" signaling pathway in schizophrenia. Several human studies suggest hyperstimulation of NRG1-ErbB4 signaling as a plausible pathomechanism; however, little is known about the significance of stage-, brain area-, or neural cell type-specific NRG1-ErbB4 hyperactivity for disease-relevant brain endophenotypes. To address these spatiotemporal aspects, we generated transgenic mice for Cre recombinase-mediated overexpression of cystein-rich domain (CRD) NRG1, the most prominent NRG1 isoform in the brain. A comparison of "brain-wide" vs cell type-specific CRD-NRG1 overexpressing mice revealed that pathogenic CRD-NRG1 signals for ventricular enlargement and neuroinflammation originate outside glutamatergic neurons and suggests a subcortical function of CRD-NRG1 in the control of body weight. Embryonic onset of CRD-NRG1 in glutamatergic cortical networks resulted in reduced inhibitory neurotransmission and locomotor hyperactivity. Our findings identify ventricular enlargement and locomotor hyperactivity, 2 main endophenotypes of schizophrenia, as specific consequences of spatiotemporally distinct expression profiles of hyperactivated CRD-NRG1 signaling.
Collapse
Affiliation(s)
- Tilmann Götze
- Department of Neurogenetics, Max-Planck-Institute of Experimental Medicine, Goettingen, Germany,Cellular Neurophysiology, Hannover Medical School, Hannover, Germany
| | - Maria Clara Soto-Bernardini
- Department of Neurogenetics, Max-Planck-Institute of Experimental Medicine, Goettingen, Germany,Present address: Center for Research in Biotechnology (CIB)/Costa Rica Institute of Technology (TEC), Cartago, Costa Rica
| | - Mingyue Zhang
- Laboratory of Molecular Psychiatry, Department of Mental Health, Westfälische Wilhelm-University of Münster, Münster, Germany
| | - Hendrik Mießner
- Cellular Neurophysiology, Hannover Medical School, Hannover, Germany,Present address: Department of Pharmacology, University of Cambridge, Cambridge, UK
| | - Lisa Linhoff
- Department of Neurogenetics, Max-Planck-Institute of Experimental Medicine, Goettingen, Germany,Department of Neurology, University Medicine Göttingen (UMG), Göttingen, Germany
| | - Magdalena M Brzózka
- Department of Psychiatry, Ludwig-Maximilian-University Munich, Munich, Germany
| | - Viktorija Velanac
- Department of Neurogenetics, Max-Planck-Institute of Experimental Medicine, Goettingen, Germany
| | - Christian Dullin
- Institute for Diagnostic and Interventional Radiology, University Medical Center, Goettingen, Germany,Translational Molecular Imaging, Max-Planck-Institute of Experimental Medicine, Goettingen, Germany,Italian Synchrotron “Elettra,"Trieste, Italy
| | - Fernanda Ramos-Gomes
- Translational Molecular Imaging, Max-Planck-Institute of Experimental Medicine, Goettingen, Germany
| | - Maja Peng
- Laboratory of Molecular Psychiatry, Department of Mental Health, Westfälische Wilhelm-University of Münster, Münster, Germany
| | - Hümeyra Husseini
- Laboratory of Molecular Psychiatry, Department of Mental Health, Westfälische Wilhelm-University of Münster, Münster, Germany
| | - Eva Schifferdecker
- Laboratory of Molecular Psychiatry, Department of Mental Health, Westfälische Wilhelm-University of Münster, Münster, Germany
| | - Robert Fledrich
- Institute of Anatomy, University of Leipzig, Leipzig, Germany
| | - Michael W Sereda
- Department of Neurogenetics, Max-Planck-Institute of Experimental Medicine, Goettingen, Germany,Department of Neurology, University Medicine Göttingen (UMG), Göttingen, Germany
| | - Katrin Willig
- Center for Nanoscale Microscopy and Molecular Physiology of the Brain, University Medical Center Göttingen, Göttingen, Germany,Max Planck Institute of Experimental Medicine, Göttingen, Germany
| | - Frauke Alves
- Institute for Diagnostic and Interventional Radiology, University Medical Center, Goettingen, Germany,Translational Molecular Imaging, Max-Planck-Institute of Experimental Medicine, Goettingen, Germany
| | - Moritz J Rossner
- Department of Psychiatry, Ludwig-Maximilian-University Munich, Munich, Germany
| | - Klaus-Armin Nave
- Department of Neurogenetics, Max-Planck-Institute of Experimental Medicine, Goettingen, Germany
| | - Weiqi Zhang
- Laboratory of Molecular Psychiatry, Department of Mental Health, Westfälische Wilhelm-University of Münster, Münster, Germany
| | - Markus H Schwab
- Department of Neurogenetics, Max-Planck-Institute of Experimental Medicine, Goettingen, Germany,Cellular Neurophysiology, Hannover Medical School, Hannover, Germany,Department of Neuropathology, University Hospital Leipzig, Leipzig, Germany,To whom correspondence should be addressed; tel: +49-341-97-25677; fax: +49-341-97-15049, e-mail:
| |
Collapse
|
8
|
Chen P, Jing H, Xiong M, Zhang Q, Lin D, Ren D, Wang S, Yin D, Chen Y, Zhou T, Li B, Fei E, Pan BX. Spine impairment in mice high-expressing neuregulin 1 due to LIMK1 activation. Cell Death Dis 2021; 12:403. [PMID: 33854034 PMCID: PMC8047019 DOI: 10.1038/s41419-021-03687-8] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/18/2020] [Revised: 03/30/2021] [Accepted: 03/30/2021] [Indexed: 02/08/2023]
Abstract
The genes encoding for neuregulin1 (NRG1), a growth factor, and its receptor ErbB4 are both risk factors of major depression disorder and schizophrenia (SZ). They have been implicated in neural development and synaptic plasticity. However, exactly how NRG1 variations lead to SZ remains unclear. Indeed, NRG1 levels are increased in postmortem brain tissues of patients with brain disorders. Here, we studied the effects of high-level NRG1 on dendritic spine development and function. We showed that spine density in the prefrontal cortex and hippocampus was reduced in mice (ctoNrg1) that overexpressed NRG1 in neurons. The frequency of miniature excitatory postsynaptic currents (mEPSCs) was reduced in both brain regions of ctoNrg1 mice. High expression of NRG1 activated LIMK1 and increased cofilin phosphorylation in postsynaptic densities. Spine reduction was attenuated by inhibiting LIMK1 or blocking the NRG1–LIMK1 interaction, or by restoring NRG1 protein level. These results indicate that a normal NRG1 protein level is necessary for spine homeostasis and suggest a pathophysiological mechanism of abnormal spines in relevant brain disorders.
Collapse
Affiliation(s)
- Peng Chen
- School of Life Sciences, Nanchang University, Nanchang, 330031, China.,Institute of Life Science, Nanchang University, Nanchang, 330031, China
| | - Hongyang Jing
- School of Life Sciences, Nanchang University, Nanchang, 330031, China.,Institute of Life Science, Nanchang University, Nanchang, 330031, China
| | - Mingtao Xiong
- Institute of Life Science, Nanchang University, Nanchang, 330031, China
| | - Qian Zhang
- School of Basic Medical Sciences, Nanchang University, Nanchang, 330031, China
| | - Dong Lin
- School of Life Sciences, Nanchang University, Nanchang, 330031, China.,Institute of Life Science, Nanchang University, Nanchang, 330031, China
| | - Dongyan Ren
- School of Life Sciences, Nanchang University, Nanchang, 330031, China.,Institute of Life Science, Nanchang University, Nanchang, 330031, China
| | - Shunqi Wang
- School of Life Sciences, Nanchang University, Nanchang, 330031, China.,Institute of Life Science, Nanchang University, Nanchang, 330031, China
| | - Dongmin Yin
- Key Laboratory of Brain Functional Genomics, Ministry of Education and Shanghai, School of Life Science, East China Normal University, Shanghai, 200062, China
| | - Yongjun Chen
- South China Research Center for Acupuncture and Moxibustion, Medical College of Acu-Moxi and Rehabilitation, Guangzhou University of Chinese Medicine, Guangzhou, 510006, China
| | - Tian Zhou
- School of Basic Medical Sciences, Nanchang University, Nanchang, 330031, China
| | - Baoming Li
- Institute of Life Science, Nanchang University, Nanchang, 330031, China
| | - Erkang Fei
- School of Life Sciences, Nanchang University, Nanchang, 330031, China. .,Institute of Life Science, Nanchang University, Nanchang, 330031, China.
| | - Bing-Xing Pan
- School of Life Sciences, Nanchang University, Nanchang, 330031, China. .,Institute of Life Science, Nanchang University, Nanchang, 330031, China.
| |
Collapse
|
9
|
Luo L, Kang Y, Zeng F, Lin Y, Feng Y, Li M, Li F. Research Progress of Cognitive Impairment in Post-Traumatic Stress Disorder. Health (London) 2021. [DOI: 10.4236/health.2021.132014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
|
10
|
Arghir A, Papuc SM, Tutulan‐Cunita A, Erbescu A, Loddo S, Genovese S, Ciocca L, Goldoni M, Piscopo C, Bernardini L, Novelli A, Budisteanu M. Autism and severe clinical phenotype in a patient with 8p21.2p11.21 deletion: Case report and literature review. Clin Case Rep 2021; 9:314-321. [PMID: 33505690 PMCID: PMC7813129 DOI: 10.1002/ccr3.3523] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/16/2020] [Revised: 07/20/2020] [Accepted: 10/20/2020] [Indexed: 02/02/2023] Open
Abstract
Interstitial 8p deletions were previously described, in literature and databases, in approximately 30 patients with neurodevelopmental disorders. We report on a novel patient with a 8p21.2p11.21 deletion presenting a clinical phenotype that includes severe intellectual disability, microcephaly, epilepsy, and autism, the latter having been rarely associated with this genetic defect.
Collapse
Affiliation(s)
- Aurora Arghir
- Victor Babes National Institute of PathologyBucharestRomania
| | | | | | - Alina Erbescu
- Victor Babes National Institute of PathologyBucharestRomania
| | - Sara Loddo
- Bambino Gesù Children's HospitalIRCCSRomeItaly
| | | | | | - Marina Goldoni
- IRCCS Casa Sollievo della Sofferenza FoundationSan Giovanni RotondoItaly
| | | | - Laura Bernardini
- IRCCS Casa Sollievo della Sofferenza FoundationSan Giovanni RotondoItaly
| | | | - Magdalena Budisteanu
- Victor Babes National Institute of PathologyBucharestRomania
- Prof. Dr. Alex. Obregia Clinical Hospital of PsychiatryBucharestRomania
- Titu Maiorescu UniversityBucharestRomania
| |
Collapse
|
11
|
Czarnek M, Bereta J. Proteolytic Processing of Neuregulin 2. Mol Neurobiol 2019; 57:1799-1813. [PMID: 31838721 PMCID: PMC7118043 DOI: 10.1007/s12035-019-01846-9] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2019] [Accepted: 11/25/2019] [Indexed: 01/17/2023]
Abstract
Neuregulin 2 (NRG2) belongs to the EGF family of growth factors. Most of this family members require proteolytic cleavage to liberate their ectodomains capable of binding and activating their cognate ErbB receptors. To date, most of the studies investigating proteolytic processing of neuregulins focused on NRG1, which was shown to undergo ectodomain shedding by several ADAM proteases and BACE1 and the remaining fragment was further cleaved by γ-secretase. Recently, NRG2 attracted more attention due to its role in the neurogenesis and modulation of behaviors associated with psychiatric disorders. In this study, we used genetic engineering methods to identify proteases involved in proteolytic processing of murine NRG2. Using non-neuronal cell lines as well as cultures of primary hippocampal neurons, we demonstrated that the major proteases responsible for releasing NRG2 ectodomain are ADAM10 and BACE2. Co-expression of NRG2 and BACE2 in neurons of certain brain structures including medulla oblongata and cerebellar deep nuclei was confirmed via immunohistochemical staining. The cleavage of NRG2 by ADAM10 or BACE2 generates a C-terminal fragment that serves as a substrate for γ-secretase. We also showed that murine NRG2 is subject to post-translational modifications, substantial glycosylation of its extracellular part, and phosphorylation of the cytoplasmic tail.
Collapse
Affiliation(s)
- Maria Czarnek
- Department of Cell Biochemistry, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University in Kraków, Gronostajowa 7, 30-387, Kraków, Poland.
| | - Joanna Bereta
- Department of Cell Biochemistry, Faculty of Biochemistry, Biophysics and Biotechnology, Jagiellonian University in Kraków, Gronostajowa 7, 30-387, Kraków, Poland.
| |
Collapse
|
12
|
Clarke DJ, Chohan TW, Kassem MS, Smith KL, Chesworth R, Karl T, Kuligowski MP, Fok SY, Bennett MR, Arnold JC. Neuregulin 1 Deficiency Modulates Adolescent Stress-Induced Dendritic Spine Loss in a Brain Region-Specific Manner and Increases Complement 4 Expression in the Hippocampus. Schizophr Bull 2019; 45:339-349. [PMID: 29566220 PMCID: PMC6403066 DOI: 10.1093/schbul/sby029] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/20/2022]
Abstract
One neuropathological feature of schizophrenia is a diminished number of dendritic spines in the prefrontal cortex and hippocampus. The neuregulin 1 (Nrg1) system is involved in the plasticity of dendritic spines, and chronic stress decreases dendritic spine densities in the prefrontal cortex and hippocampus. Here, we aimed to assess whether Nrg1 deficiency confers vulnerability to the effects of adolescent stress on dendritic spine plasticity. We also assessed other schizophrenia-relevant neurobiological changes such as microglial cell activation, loss of parvalbumin (PV) interneurons, and induction of complement factor 4 (C4). Adolescent male wild-type (WT) and Nrg1 heterozygous mice were subjected to chronic restraint stress before their brains underwent Golgi impregnation or immunofluorescent staining of PV interneurons, microglial cells, and C4. Stress in WT mice promoted dendritic spine loss and microglial cell activation in the prefrontal cortex and the hippocampus. However, Nrg1 deficiency rendered mice resilient to stress-induced dendritic spine loss in the infralimbic cortex and the CA3 region of the hippocampus without affecting stress-induced microglial cell activation in these brain regions. Nrg1 deficiency and adolescent stress combined to trigger increased dendritic spine densities in the prelimbic cortex. In the hippocampal CA1 region, Nrg1 deficiency accentuated stress-induced dendritic spine loss. Nrg1 deficiency increased C4 protein and decreased C4 mRNA expression in the hippocampus, and the number of PV interneurons in the basolateral amygdala. This study demonstrates that Nrg1 modulates the impact of stress on the adolescent brain in a region-specific manner. It also provides first evidence of a link between Nrg1 and C4 systems in the hippocampus.
Collapse
Affiliation(s)
- David J Clarke
- Brain and Mind Centre, University of Sydney, Sydney, Australia,Department of Pharmacology, University of Sydney, Sydney, Australia
| | - Tariq W Chohan
- Brain and Mind Centre, University of Sydney, Sydney, Australia,Department of Pharmacology, University of Sydney, Sydney, Australia
| | | | - Kristie L Smith
- Brain and Mind Centre, University of Sydney, Sydney, Australia
| | - Rose Chesworth
- School of Medicine, Western Sydney University, Sydney, Australia
| | - Tim Karl
- School of Medicine, Western Sydney University, Sydney, Australia,Neuroscience Research Australia, Randwick, Australia,School of Medical Sciences, University of New South Wales, Sydney, Australia
| | - Michael P Kuligowski
- Australian Microscopy & Microanalysis Research Facility, University of Sydney, Camperdown, Australia
| | - Sandra Y Fok
- Brain and Mind Centre, University of Sydney, Sydney, Australia
| | | | - Jonathon C Arnold
- Brain and Mind Centre, University of Sydney, Sydney, Australia,Department of Pharmacology, University of Sydney, Sydney, Australia,To whom correspondence should be addressed; Brain and Mind Centre, Level 6, Building F, 94 Mallett Street, Camperdown, NSW 2050, Australia; tel: +61-29351-0812, e-mail:
| |
Collapse
|
13
|
Nrg1 deficiency modulates the behavioural effects of prenatal stress in mice. Prog Neuropsychopharmacol Biol Psychiatry 2019; 88:86-95. [PMID: 29964074 DOI: 10.1016/j.pnpbp.2018.06.013] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/16/2017] [Revised: 06/21/2018] [Accepted: 06/23/2018] [Indexed: 11/23/2022]
Abstract
Little is known about the exact genes that confer vulnerability or resilience to environmental stressors during early neurodevelopment. Partial genetic deletion of neuregulin 1 (Nrg1) moderates the neurobehavioural effects of stressors applied in adolescence and adulthood, however, no study has yet examined its impact on prenatal stress. Here we examined whether Nrg1 deficiency in mice modulated the impact of prenatal stress on various behaviours in adulthood. Male heterozygous Nrg1 mice were mated with wild-type female mice who then underwent daily restraint stress from days 13 to 19 of gestation. Surprisingly, prenatal stress had overall beneficial effects by facilitating sensorimotor gating, increasing sociability, decreasing depressive-like behaviour, and improving spatial memory in adulthood. Such benefits were not due to any increase in maternal care, as prenatal stress decreased nurturing of the offspring. Nrg1 deficiency negated the beneficial behavioural effects of prenatal stress on all measures except sociability. However, Nrg1 deficiency interacted with prenatal stress to trigger locomotor hyperactivity. Nrg1 deficiency, prenatal stress or their combination failed to alter acute stress-induced plasma corticosterone concentrations. Collectively these results demonstrate that Nrg1 deficiency moderates the effects of prenatal stress on adult behaviour, but it does so in a complex, domain-specific fashion.
Collapse
|
14
|
Association of functional polymorphisms in 3'-untranslated regions of COMT, DISC1, and DTNBP1 with schizophrenia: a meta-analysis. Psychiatr Genet 2019; 28:110-119. [PMID: 30252773 DOI: 10.1097/ypg.0000000000000210] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/18/2022]
Abstract
INTRODUCTION In recent years, various studies have accumulated evidence of the involvement of single nucleotide polymorphisms (SNPs) in introns and exons in schizophrenia. The association of functional SNPs in the 3'-untranslated regions with schizophrenia has been explored in a number of studies, but the results are inconclusive because of limited meta-analyses. To systematically analyze the association between SNPs in 3'-untranslated regions and schizophrenia, we conducted a meta-analysis by combining all available studies on schizophrenia candidate genes. MATERIALS AND METHODS We searched candidate genes from the schizophrenia database and performed a comprehensive meta-analysis using all the available data up to August 2017. The association between susceptible SNPs and schizophrenia was assessed by the pooled odds ratio with 95% confidence interval using fixed-effect and random-effect models. RESULTS A total of 21 studies including 8291 cases and 9638 controls were used for meta-analysis. Three investigated SNPs were rs165599, rs3737597, and rs1047631 of COMT, DISC1, and DTNBP1, respectively. Our results suggested that rs3737597 showed a significant association with schizophrenia in Europeans (odds ratio: 1.584, P: 0.002, 95% confidence interval: 1.176-2.134) under a random-effect framework. CONCLUSION This meta-analysis indicated that rs3737597 of DISC1 was significantly associated with schizophrenia in Europeans, and it can be suggested as an ethnic-specific risk genetic factor.
Collapse
|
15
|
Genetic recovery of ErbB4 in adulthood partially restores brain functions in null mice. Proc Natl Acad Sci U S A 2018; 115:13105-13110. [PMID: 30498032 DOI: 10.1073/pnas.1811287115] [Citation(s) in RCA: 29] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Neurotrophic factor NRG1 and its receptor ErbB4 play a role in GABAergic circuit assembly during development. ErbB4 null mice possess fewer interneurons, have decreased GABA release, and show impaired behavior in various paradigms. In addition, NRG1 and ErbB4 have also been implicated in regulating GABAergic transmission and plasticity in matured brains. However, current ErbB4 mutant strains are unable to determine whether phenotypes in adult mutant mice result from abnormal neural development. This important question, a glaring gap in understanding NRG1-ErbB4 function, was addressed by using two strains of mice with temporal control of ErbB4 deletion and expression, respectively. We found that ErbB4 deletion in adult mice impaired behavior and GABA release but had no effect on neuron numbers and morphology. On the other hand, some deficits due to the ErbB4 null mutation during development were alleviated by restoring ErbB4 expression at the adult stage. Together, our results indicate a critical role of NRG1-ErbB4 signaling in GABAergic transmission and behavior in adulthood and suggest that restoring NRG1-ErbB4 signaling at the postdevelopmental stage might benefit relevant brain disorders.
Collapse
|
16
|
Uddin M, Ratanatharathorn A, Armstrong D, Kuan PF, Aiello AE, Bromet EJ, Galea S, Koenen KC, Luft B, Ressler KJ, Wildman DE, Nievergelt CM, Smith A. Epigenetic meta-analysis across three civilian cohorts identifies NRG1 and HGS as blood-based biomarkers for post-traumatic stress disorder. Epigenomics 2018; 10:1585-1601. [PMID: 30456986 DOI: 10.2217/epi-2018-0049] [Citation(s) in RCA: 36] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
AIM Trauma exposure is a necessary, but not deterministic, contributor to post-traumatic stress disorder (PTSD). Epigenetic factors may distinguish between trauma-exposed individuals with versus without PTSD. MATERIALS & METHODS We conducted a meta-analysis of PTSD epigenome-wide association studies in trauma-exposed cohorts drawn from civilian contexts. Whole blood-derived DNA methylation levels were analyzed in 545 study participants, drawn from the three civilian cohorts participating in the PTSD working group of the Psychiatric Genomics Consortium. RESULTS Two CpG sites significantly associated with current PTSD in NRG1 (cg23637605) and in HGS (cg19577098). CONCLUSION PTSD is associated with differential methylation, measured in blood, within HGS and NRG1 across three civilian cohorts.
Collapse
Affiliation(s)
- Monica Uddin
- Carl R Woese Institute for Genomic Biology, University of Illinois at Urbana-Champaign, 1206 West Gregory Drive, Urbana, IL 61801, USA.,Department of Psychology, University of Illinois Urbana-Champaign, 603 East Daniel St, Champaign, IL 61820, USA
| | - Andrew Ratanatharathorn
- Department of Epidemiology, Mailman School of Public Health, Columbia University, 722 West 168th St, NY 10032, USA
| | - Don Armstrong
- Carl R Woese Institute for Genomic Biology, University of Illinois at Urbana-Champaign, 1206 West Gregory Drive, Urbana, IL 61801, USA
| | - Pei-Fen Kuan
- Department of Applied Mathematics & Statistics, Stony Brook University, John S Toll Drive, Stony Brook, NY 11794, USA
| | - Allison E Aiello
- Department of Epidemiology, Gillings School of Public Health, University of North Carolina, 135 Dauer Drive, Chapel Hill, NC 27599, USA
| | - Evelyn J Bromet
- Department of Psychiatry, Stony Brook University School of Medicine, 101 Nicolls Rd, Stony Brook, NY 11794, USA
| | - Sandro Galea
- Boston University School of Public Health, 715 Albany St, Boston, MA 02118, USA
| | - Karestan C Koenen
- Department of Epidemiology, Harvard TH Chan School of Public Health, 677 Huntington Avenue, Boston, MA 02115, USA.,Psychiatic & Neurodevelopmental Genetics Unit & Department of Psychiatry, Massachusetts General Hospital, Simches Research Building, 185 Cambridge Street, Boston, MA 02114, USA.,Stanley Center for Psychiatric Research, Broad Institute, Cambridge, MA 02142, USA
| | - Benjamin Luft
- Department of Medicine, Stony Brook University School of Medicine, 101 Nicolls Road, Stony Brook, NY 11794, USA
| | - Kerry J Ressler
- Department of Psychiatry, McLean Hospital, Harvard Medical School, 115 Mill Street, Belmont, MA 02478, USA
| | - Derek E Wildman
- Carl R Woese Institute for Genomic Biology, University of Illinois at Urbana-Champaign, 1206 West Gregory Drive, Urbana, IL 61801, USA.,Department of Molecular & Integrative Physiology, University of Illinois at Urbana-Champaign, 407 South Goodwin Avenue, Urbana, IL 61801, USA
| | - Caroline M Nievergelt
- Department of Psychiatry, University of California San Diego School of Medicine, 9500 Gilman Dr, La Jolla, CA 92093, USA.,VA Center of Excellence for Stress & Mental Health, VA San Diego Healthcare System, 3350 La Jolla Village Drive, San Diego, CA 92161, USA
| | - Alicia Smith
- Department of Psychiatry & Behavioral Sciences & Department of Obstetrics & Gynecology, Emory University School of Medicine, 100 Woodruff Circle, Atlanta, GA 30322, USA
| |
Collapse
|
17
|
Olaya JC, Heusner CL, Matsumoto M, Shannon Weickert C, Karl T. Schizophrenia-relevant behaviours of female mice overexpressing neuregulin 1 type III. Behav Brain Res 2018; 353:227-235. [DOI: 10.1016/j.bbr.2018.03.026] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/21/2017] [Revised: 03/15/2018] [Accepted: 03/15/2018] [Indexed: 12/20/2022]
|
18
|
Crocker CE, Tibbo PG. Confused Connections? Targeting White Matter to Address Treatment Resistant Schizophrenia. Front Pharmacol 2018; 9:1172. [PMID: 30405407 PMCID: PMC6201564 DOI: 10.3389/fphar.2018.01172] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/11/2018] [Accepted: 09/28/2018] [Indexed: 12/14/2022] Open
Abstract
Despite development of comprehensive approaches to treat schizophrenia and other psychotic disorders and improve outcomes, there remains a proportion (approximately one-third) of patients who are treatment resistant and will not have remission of psychotic symptoms despite adequate trials of pharmacotherapy. This level of treatment response is stable across all stages of the spectrum of psychotic disorders, including early phase psychosis and chronic schizophrenia. Our current pharmacotherapies are beneficial in decreasing positive symptomology in most cases, however, with little to no impact on negative or cognitive symptoms. Not all individuals with treatment resistant psychosis unfortunately, even benefit from the potential pharmacological reductions in positive symptoms. The existing pharmacotherapy for psychosis is targeted at neurotransmitter receptors. The current first and second generation antipsychotic medications all act on dopamine type 2 receptors with the second generation drugs also interacting significantly with serotonin type 1 and 2 receptors, and with varying pharmacodynamic profiles overall. This focus on developing dopaminergic/serotonergic antipsychotics, while beneficial, has not reduced the proportion of patients experiencing treatment resistance to date. Another pharmacological approach is imperative to address treatment resistance both for response overall and for negative symptoms in particular. There is research suggesting that changes in white matter integrity occur in schizophrenia and these may be more associated with cognition and even negative symptomology. Here we review the evidence that white matter abnormalities in the brain may be contributing to the symptomology of psychotic disorders. Additionally, we propose that white matter may be a viable pharmacological target for pharmacoresistant schizophrenia and discuss current treatments in development for schizophrenia that target white matter.
Collapse
Affiliation(s)
- Candice E Crocker
- Department of Psychiatry, Dalhousie University, Halifax, NS, Canada.,Department of Diagnostic Imaging, Nova Scotia Health Authority, Halifax, NS, Canada
| | - Philip G Tibbo
- Department of Psychiatry, Dalhousie University, Halifax, NS, Canada
| |
Collapse
|
19
|
Waddington JL, O'Tuathaigh CM. Modelling the neuromotor abnormalities of psychotic illness: Putative mechanisms and systems dysfunction. Schizophr Res 2018; 200:12-19. [PMID: 28867516 DOI: 10.1016/j.schres.2017.08.022] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/07/2017] [Revised: 08/11/2017] [Accepted: 08/16/2017] [Indexed: 12/20/2022]
Abstract
Limitations in access to antipsychotic-naïve patients and in the incisiveness of studies that can be conducted on them, together with the inevitability of subsequent antipsychotic treatment, indicate an enduring role for animal models that can inform on the pathobiology of neuromotor abnormalities in schizophrenia and related psychotic illness. This review focusses particularly on genetically modified mouse models that involve genes associated with risk for schizophrenia and with mechanisms implicated in the neuromotor abnormalities evident in psychotic patients, as well as developmental models that seek to mirror the trajectory, phenomenology and putative pathophysiology of psychotic illness. Such abnormalities are inconsistent and subtle in mice mutant for some schizophrenia risk genes but more evident for others. The phenotype of dopaminergic and glutamatergic mutants indicates the involvement of these mechanisms, informs on the roles of specific receptor subtypes, and implicates the interplay of cortical and subcortical processes. Developmental models suggest a criticality in the timing of early adversity for diversity in the relative emergence of psychological symptoms vis-à-vis neuromotor abnormalities in the overall psychosis phenotype. These findings elaborate current concepts of dysfunction in a neuronal network linking the cerebral cortex, basal ganglia, thalamus and cerebellum. Both findings in model systems and clinical evidence converge in indicating that any distinction between 'psychomotor' and 'neuromotor' abnormality is artificial and arbitrary due to a unitary origin in developmentally determined systems/network dysfunction that underlies the lifetime trajectory of psychotic illness.
Collapse
Affiliation(s)
- John L Waddington
- Molecular & Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland; Jiangsu Key Laboratory of Translational Research and Therapy for Neuro-Psychiatric-Diseases, Department of Pharmacology, College of Pharmaceutical Sciences, Soochow University, Suzhou, China.
| | | |
Collapse
|
20
|
Wang H, Xu J, Lazarovici P, Quirion R, Zheng W. cAMP Response Element-Binding Protein (CREB): A Possible Signaling Molecule Link in the Pathophysiology of Schizophrenia. Front Mol Neurosci 2018; 11:255. [PMID: 30214393 PMCID: PMC6125665 DOI: 10.3389/fnmol.2018.00255] [Citation(s) in RCA: 246] [Impact Index Per Article: 41.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/03/2018] [Accepted: 07/06/2018] [Indexed: 12/17/2022] Open
Abstract
Dopamine is a brain neurotransmitter involved in the pathology of schizophrenia. The dopamine hypothesis states that, in schizophrenia, dopaminergic signal transduction is hyperactive. The cAMP-response element binding protein (CREB) is an intracellular protein that regulates the expression of genes that are important in dopaminergic neurons. Dopamine affects the phosphorylation of CREB via G protein-coupled receptors. Neurotrophins, such as brain derived growth factor (BDNF), are critical regulators during neurodevelopment and synaptic plasticity. The CREB is one of the major regulators of neurotrophin responses since phosphorylated CREB binds to a specific sequence in the promoter of BDNF and regulates its transcription. Moreover, susceptibility genes associated with schizophrenia also target and stimulate the activity of CREB. Abnormalities of CREB expression is observed in the brain of individuals suffering from schizophrenia, and two variants (-933T to C and -413G to A) were found only in schizophrenic patients. The CREB was also involved in the therapy of animal models of schizophrenia. Collectively, these findings suggest a link between CREB and the pathophysiology of schizophrenia. This review provides an overview of CREB structure, expression, and biological functions in the brain and its interaction with dopamine signaling, neurotrophins, and susceptibility genes for schizophrenia. Animal models in which CREB function is modulated, by either overexpression of the protein or knocked down through gene deletion/mutation, implicating CREB in schizophrenia and antipsychotic drugs efficacy are also discussed. Targeting research and drug development on CREB could potentially accelerate the development of novel medications against schizophrenia.
Collapse
Affiliation(s)
- Haitao Wang
- Department of Neuropharmacology and Drug Discovery, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China
| | - Jiangping Xu
- Department of Neuropharmacology and Drug Discovery, School of Pharmaceutical Sciences, Southern Medical University, Guangzhou, China
| | - Philip Lazarovici
- School of Pharmacy Institute for Drug Research, Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem, Israel
| | - Remi Quirion
- Douglas Mental Health University Institute, McGill University, Montreal, QC, Canada
| | - Wenhua Zheng
- Faculty of Health Sciences, University of Macau, Taipa, China
| |
Collapse
|
21
|
Olaya JC, Heusner CL, Matsumoto M, Sinclair D, Kondo MA, Karl T, Shannon Weickert C. Overexpression of Neuregulin 1 Type III Confers Hippocampal mRNA Alterations and Schizophrenia-Like Behaviors in Mice. Schizophr Bull 2018; 44:865-875. [PMID: 28981869 PMCID: PMC6007747 DOI: 10.1093/schbul/sbx122] [Citation(s) in RCA: 26] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
Neuregulin 1 (NRG1) is a schizophrenia candidate gene whose protein product is involved in neuronal migration, survival, and synaptic plasticity via production of specific isoforms. Importantly, NRG1 type III (NRG1 III) mRNA is increased in humans inheriting a schizophrenia risk haplotype for the NRG1 gene (HapICE), and NRG1 protein levels can be elevated in schizophrenia. The nature by which NRG1 type III overexpression results in schizophrenia-like behavior and brain pathology remains unclear, therefore we constructed a transgenic mouse with Nrg1 III overexpression in forebrain neurons (CamKII kinase+). Here, we demonstrate construct validity for this mouse model, as juvenile and adult Nrg1 III transgenic mice exhibit an overexpression of Nrg1 III mRNA and Nrg1 protein in multiple brain regions. Furthermore, Nrg1 III transgenic mice have face validity as they exhibit schizophrenia-relevant behavioral phenotypes including deficits in social preference, impaired fear-associated memory, and reduced prepulse inhibition. Additionally, microarray assay of hippocampal mRNA uncovered transcriptional alterations downstream of Nrg1 III overexpression, including changes in serotonin receptor 2C and angiotensin-converting enzyme. Transgenic mice did not exhibit other schizophrenia-relevant behaviors including hyperactivity, social withdrawal, or an increased vulnerability to the effects of MK-801 malate. Our results indicate that this novel Nrg1 III mouse is valid for modeling potential pathological mechanisms of some schizophrenia-like behaviors, for determining what other neurobiological changes may be downstream of elevated NRG1 III levels and for preclinically testing therapeutic strategies that may be specifically efficacious in patients with the NRG1 (HapICE) risk genotype.
Collapse
Affiliation(s)
- Juan C Olaya
- Schizophrenia Research Laboratory, Neuroscience Research Australia, Randwick, NSW, Australia,School of Psychiatry, University of New South Wales, Sydney, Australia
| | | | | | - Duncan Sinclair
- Schizophrenia Research Laboratory, Neuroscience Research Australia, Randwick, NSW, Australia,School of Psychiatry, University of New South Wales, Sydney, Australia
| | - Mari A Kondo
- Schizophrenia Research Laboratory, Neuroscience Research Australia, Randwick, NSW, Australia,School of Psychiatry, University of New South Wales, Sydney, Australia
| | - Tim Karl
- Schizophrenia Research Laboratory, Neuroscience Research Australia, Randwick, NSW, Australia,School of Medicine, Western Sydney University, Campbelltown, Australia
| | - Cynthia Shannon Weickert
- Schizophrenia Research Laboratory, Neuroscience Research Australia, Randwick, NSW, Australia,School of Psychiatry, University of New South Wales, Sydney, Australia,To whom correspondence should be addressed; Neuroscience Research Australia, Barker Street, Randwick, NSW 2031, Australia; tel: +61-2-9399-1117, fax: +61-2-9399-1005, e-mail:
| |
Collapse
|
22
|
Anand S, Govindaraju A, Vairavan V, Narayanan SK, Rajagopal R, Chellappa A, Ayyappa A, Thiagarajan K, Kumar AK, ArunKumar G. Association of Neuregulin-1 gene polymorphisms with neuro-cognitive features of schizophrenia patients from South India: A pilot study. Meta Gene 2018. [DOI: 10.1016/j.mgene.2017.12.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
23
|
Antibody-mediated stabilization of NRG1 induces behavioral and electrophysiological alterations in adult mice. Sci Rep 2018; 8:8239. [PMID: 29844389 PMCID: PMC5974084 DOI: 10.1038/s41598-018-26492-4] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2017] [Accepted: 05/08/2018] [Indexed: 01/14/2023] Open
Abstract
Neuregulin 1 (NRG1) is required for development of the central and peripheral nervous system and regulates neurotransmission in the adult. NRG1 and the gene encoding its receptor, ERBB4, are risk genes for schizophrenia, although how alterations in these genes disrupt their function has not been fully established. Studies of knockout and transgenic mice have yielded conflicting results, with both gain and loss of function resulting in similar behavioral and electrophysiological phenotypes. Here, we used high affinity antibodies to NRG1 and ErbB4 to perturb the function of the endogenous proteins in adult mice. Treatment with NRG1 antibodies that block receptor binding caused behavioral alterations associated with schizophrenia, including, hyper-locomotion and impaired pre-pulse inhibition of startle (PPI). Electrophysiological analysis of brain slices from anti-NRG1 treated mice revealed reduced synaptic transmission and enhanced paired-pulse facilitation. In contrast, mice treated with more potent ErbB4 function blocking antibodies did not display behavioral alterations, suggesting a receptor independent mechanism of the anti-NRG1-induced phenotypes. We demonstrate that anti-NRG1 causes accumulation of the full-length transmembrane protein and increases phospho-cofilin levels, which has previously been linked to impaired synaptic transmission, indicating enhancement of non-canonical NRG1 signaling could mediate the CNS effects.
Collapse
|
24
|
Bousman CA, Cropley V, Klauser P, Hess JL, Pereira A, Idrizi R, Bruggemann J, Mostaid MS, Lenroot R, Weickert TW, Glatt SJ, Everall IP, Sundram S, Zalesky A, Weickert CS, Pantelis C. Neuregulin-1 (NRG1) polymorphisms linked with psychosis transition are associated with enlarged lateral ventricles and white matter disruption in schizophrenia. Psychol Med 2018; 48:801-809. [PMID: 28826413 DOI: 10.1017/s0033291717002173] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Abstract
BACKGROUND Two single-nucleotide polymorphisms (SNPs) (rs4281084 and rs12155594) within the neuregulin-1 (NRG1) gene have been associated with psychosis transition. However, the neurobiological changes associated with these SNPs remain unclear. We aimed to determine what relationship these two SNPs have on lateral ventricular volume and white matter integrity, as abnormalities in these brain structures are some of the most consistent in schizophrenia. METHODS Structural (n = 370) and diffusion (n = 465) magnetic resonance imaging data were obtained from affected and unaffected individuals predominantly of European descent. The SNPs rs4281084, rs12155594, and their combined allelic load were examined for their effects on lateral ventricular volume, fractional anisotropy (FA) as well as axial (AD) and radial (RD) diffusivity. Additional exploratory analyses assessed NRG1 effects on gray matter volume, cortical thickness, and surface area throughout the brain. RESULTS Individuals with a schizophrenia age of onset ⩽25 and a combined allelic load ⩾3 NRG1 risk alleles had significantly larger right (up to 50%, p adj = 0.01) and left (up to 45%, p adj = 0.05) lateral ventricle volumes compared with those with allelic loads of less than three. Furthermore, carriers of three or more risk alleles, regardless of age of onset and case status, had significantly reduced FA and elevated RD but stable AD in the frontal cortex compared with those carrying fewer than three risk alleles. CONCLUSIONS Our findings build on a growing body of research supporting the functional importance of genetic variation within the NRG1 gene and complement previous findings implicating the rs4281084 and rs12155594 SNPs as markers for psychosis transition.
Collapse
Affiliation(s)
- C A Bousman
- Department of Psychiatry,Melbourne Neuropsychiatry Centre, The University of Melbourne and Melbourne Health,Carlton South, VIC,Australia
| | - V Cropley
- Department of Psychiatry,Melbourne Neuropsychiatry Centre, The University of Melbourne and Melbourne Health,Carlton South, VIC,Australia
| | - P Klauser
- Department of Psychiatry,Melbourne Neuropsychiatry Centre, The University of Melbourne and Melbourne Health,Carlton South, VIC,Australia
| | - J L Hess
- Psychiatric Genetic Epidemiology & Neurobiology Laboratory (PsychGENe Lab), Departments of Psychiatry and Behavioral Sciences and Neuroscience and Physiology,SUNY Upstate Medical University,Syracuse, New York
| | - A Pereira
- Florey Institute of Neuroscience and Mental Health, The University of Melbourne,Parkville, VIC,Australia
| | - R Idrizi
- Florey Institute of Neuroscience and Mental Health, The University of Melbourne,Parkville, VIC,Australia
| | - J Bruggemann
- Schizophrenia Research Institute,Sydney,Australia
| | - M S Mostaid
- Department of Psychiatry,Melbourne Neuropsychiatry Centre, The University of Melbourne and Melbourne Health,Carlton South, VIC,Australia
| | - R Lenroot
- Schizophrenia Research Institute,Sydney,Australia
| | - T W Weickert
- Schizophrenia Research Institute,Sydney,Australia
| | - S J Glatt
- Psychiatric Genetic Epidemiology & Neurobiology Laboratory (PsychGENe Lab), Departments of Psychiatry and Behavioral Sciences and Neuroscience and Physiology,SUNY Upstate Medical University,Syracuse, New York
| | - I P Everall
- Department of Psychiatry,Melbourne Neuropsychiatry Centre, The University of Melbourne and Melbourne Health,Carlton South, VIC,Australia
| | - S Sundram
- Florey Institute of Neuroscience and Mental Health, The University of Melbourne,Parkville, VIC,Australia
| | - A Zalesky
- Department of Psychiatry,Melbourne Neuropsychiatry Centre, The University of Melbourne and Melbourne Health,Carlton South, VIC,Australia
| | - C S Weickert
- Schizophrenia Research Institute,Sydney,Australia
| | - C Pantelis
- Department of Psychiatry,Melbourne Neuropsychiatry Centre, The University of Melbourne and Melbourne Health,Carlton South, VIC,Australia
| |
Collapse
|
25
|
Mostaid MS, Lee TT, Chana G, Sundram S, Shannon Weickert C, Pantelis C, Everall I, Bousman C. Elevated peripheral expression of neuregulin-1 (NRG1) mRNA isoforms in clozapine-treated schizophrenia patients. Transl Psychiatry 2017; 7:1280. [PMID: 29225331 PMCID: PMC5802529 DOI: 10.1038/s41398-017-0041-2] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/01/2017] [Revised: 07/13/2017] [Accepted: 09/23/2017] [Indexed: 12/18/2022] Open
Abstract
Differential expression of neuregulin-1 (NRG1) mRNA isoforms and proteins has been reported in schizophrenia, primarily in post-mortem brain tissue. In this study, we examined 12 NRG1 SNPs, eight NRG1 mRNA isoforms (type I, type I(Ig2), type II, type III, type IV, EGFα, EGFβ, pan-NRG1) in whole blood, and NRG1-β1 protein in serum of clozapine-treated schizophrenia patients (N = 71) and healthy controls (N = 57). In addition, using cultured peripheral blood mononuclear cells (PBMC) from 15 healthy individuals, we examined the effect of clozapine on NRG1 mRNA isoform and protein expression. We found elevated levels of NRG1 mRNA, specifically the EGFα (P = 0.0175), EGFβ (P = 0.002) and type I(Ig2) (P = 0.023) containing transcripts, but lower NRG1-β1 serum protein levels (P = 0.019) in schizophrenia patients compared to healthy controls. However, adjusting for smoking status attenuated the difference in NRG1-β1 serum levels (P = 0.050). Examination of clinical factors showed NRG1 EGFα (P = 0.02) and EGFβ (P = 0.02) isoform expression was negatively correlated with age of onset. However, we found limited evidence that NRG1 mRNA isoform or protein expression was associated with current chlorpromazine equivalent dose or clozapine plasma levels, the latter corroborated by our PBMC clozapine exposure experiment. Our SNP analysis found no robust expression quantitative trait loci. Our results represent the first comprehensive investigation of NRG1 isoforms and protein expression in the blood of clozapine-treated schizophrenia patients and suggest levels of some NRG1 transcripts are upregulated in those with schizophrenia.
Collapse
Affiliation(s)
- Md Shaki Mostaid
- 0000 0004 0452 651Xgrid.429299.dMelbourne Neuropsychiatry Center, Department of Psychiatry, The University of Melbourne & Melbourne Health, Parkville, VIC Australia ,The Cooperative Research Center (CRC) for Mental Health, Carlton, VIC Australia
| | - Ting Ting Lee
- 0000 0001 2179 088Xgrid.1008.9Center for Neural Engineering, Department of Electrical and Electronic Engineering, The University of Melbourne, Carlton, VIC Australia
| | - Gursharan Chana
- 0000 0001 2179 088Xgrid.1008.9Center for Neural Engineering, Department of Electrical and Electronic Engineering, The University of Melbourne, Carlton, VIC Australia ,Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC Australia ,0000 0004 0624 1200grid.416153.4Department of Medicine, Royal Melbourne Hospital, Parkville, VIC Australia
| | - Suresh Sundram
- Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC Australia ,NorthWestern Mental Health, Melbourne, VIC Australia ,0000 0000 9295 3933grid.419789.aDepartment of Psychiatry, School of Clinical Sciences, Monash University and Monash Health, Clayton, VIC Australia
| | - Cynthia Shannon Weickert
- 0000 0000 8696 2171grid.419558.4Schizophrenia Research Institute, Sydney, NSW Australia ,0000 0000 8900 8842grid.250407.4Schizophrenia Research Laboratory, Neuroscience Research Australia, Baker Street, Sydney, NSW Australia ,0000 0004 4902 0432grid.1005.4School of Psychiatry, Faculty of Medicine, University of New South Wales, Sydney, NSW Australia
| | - Christos Pantelis
- 0000 0004 0452 651Xgrid.429299.dMelbourne Neuropsychiatry Center, Department of Psychiatry, The University of Melbourne & Melbourne Health, Parkville, VIC Australia ,The Cooperative Research Center (CRC) for Mental Health, Carlton, VIC Australia ,0000 0001 2179 088Xgrid.1008.9Center for Neural Engineering, Department of Electrical and Electronic Engineering, The University of Melbourne, Carlton, VIC Australia ,Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC Australia ,NorthWestern Mental Health, Melbourne, VIC Australia
| | - Ian Everall
- 0000 0004 0452 651Xgrid.429299.dMelbourne Neuropsychiatry Center, Department of Psychiatry, The University of Melbourne & Melbourne Health, Parkville, VIC Australia ,The Cooperative Research Center (CRC) for Mental Health, Carlton, VIC Australia ,0000 0001 2179 088Xgrid.1008.9Center for Neural Engineering, Department of Electrical and Electronic Engineering, The University of Melbourne, Carlton, VIC Australia ,Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC Australia ,NorthWestern Mental Health, Melbourne, VIC Australia ,0000 0000 8696 2171grid.419558.4Schizophrenia Research Institute, Sydney, NSW Australia
| | - Chad Bousman
- Melbourne Neuropsychiatry Center, Department of Psychiatry, The University of Melbourne & Melbourne Health, Parkville, VIC, Australia. .,The Cooperative Research Center (CRC) for Mental Health, Carlton, VIC, Australia. .,Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia. .,Departments of Medical Genetics, Psychiatry, and Physiology & Pharmacology, University of Calgary, Calgary, AB, Canada.
| |
Collapse
|
26
|
Waddington JL, Katina S, O'Tuathaigh CMP, Bowman AW. Translational Genetic Modelling of 3D Craniofacial Dysmorphology: Elaborating the Facial Phenotype of Neurodevelopmental Disorders Through the "Prism" of Schizophrenia. Curr Behav Neurosci Rep 2017; 4:322-330. [PMID: 29201594 PMCID: PMC5694503 DOI: 10.1007/s40473-017-0136-3] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
Purpose of Review In the context of human developmental conditions, we review the conceptualisation of schizophrenia as a neurodevelopmental disorder, the status of craniofacial dysmorphology as a clinically accessible index of brain dysmorphogenesis, the ability of genetically modified mouse models of craniofacial dysmorphology to inform on the underlying dysmorphogenic process and how geometric morphometric techniques in mutant mice can extend quantitative analysis. Recent Findings Mutant mice with disruption of neuregulin-1, a gene associated meta-analytically with risk for schizophrenia, constitute proof-of-concept studies of murine facial dysmorphology in a manner analogous to clinical studies in schizophrenia. Geometric morphometric techniques informed on the topography of facial dysmorphology and identified asymmetry therein. Summary Targeted disruption in mice of genes involved in individual components of developmental processes and analysis of resultant facial dysmorphology using geometric morphometrics can inform on mechanisms of dysmorphogenesis at levels of incisiveness not possible in human subjects.
Collapse
Affiliation(s)
- John L Waddington
- Molecular & Cellular Therapeutics, Royal College of Surgeons in Ireland, St. Stephen's Green, Dublin 2, Ireland.,Jiangsu Key Laboratory of Translational Research & Therapy for Neuro-Psychiatric-Disorders and Department of Pharmacology, College of Pharmaceutical Sciences, Soochow University, Suzhou, 215123 China
| | - Stanislav Katina
- School of Mathematics and Statistics, University of Glasgow, Glasgow, G12 8QQ UK.,Institute of Mathematics and Statistics, Masaryk University, Brno, Czech Republic.,Institute of Normal and Pathological Physiology, Slovak Academy of Sciences, Bratislava, Slovakia
| | | | - Adrian W Bowman
- School of Mathematics and Statistics, University of Glasgow, Glasgow, G12 8QQ UK
| |
Collapse
|
27
|
Jagannath V, Gerstenberg M, Correll CU, Walitza S, Grünblatt E. A systematic meta-analysis of the association of Neuregulin 1 (NRG1), D-amino acid oxidase (DAO), and DAO activator (DAOA)/G72 polymorphisms with schizophrenia. J Neural Transm (Vienna) 2017; 125:89-102. [PMID: 28864885 DOI: 10.1007/s00702-017-1782-z] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2017] [Accepted: 08/23/2017] [Indexed: 02/07/2023]
Abstract
The glutamate hypothesis of schizophrenia is related to the proposed dysregulation of D-amino acid oxidase (DAO), DAO activator (DAOA)/G72, and Neuregulin 1 (NRG1) genes. Genetic studies have shown significant associations between DAO, DAOA, NRG1 single-nucleotide polymorphisms (SNPs), and schizophrenia. The systematic literature search yielded 6, 5, and 18 new studies for DAO, DAOA, and NRG1 published after 2011 and not included in the previous SchizophreniaGene (SZGene) meta-analysis. We conducted meta-analyses of 20, 23, and 48 case-control studies, respectively, to comprehensively evaluate the association of 8 DAO, 12 DAOA, and 14 NRG1 SNPs with schizophrenia. The updated meta-analyses resulted in the following findings: the C-allele of DAO rs4623951 was associated with schizophrenia across all pooled studies [Odds ratio (OR) = 0.88, 95% confidence interval (CI) = 0.79-0.98, p = 0.02, N = 3143]; however, no new reports could be included. The G-allele of DAOA rs778293 was associated with schizophrenia in Asian patients (OR = 1.17, 95% CI = 1.08-1.27, p = 0.00008, N = 6117), and the T-allele of DAOA rs3916971 was associated with schizophrenia across all studies (OR = 0.84, 95% CI = 0.73-0.96, p = 0.01, N = 1765). Again, for both SNPs, no new eligible studies were available. After adding new reports, the T-allele of NRG1 SNP8NRG241930 (rs62510682) across all studies (OR = 0.95, 95% CI = 0.91-0.997, p = 0.04, N = 22,898) and in Caucasian samples (OR = 0.95, 95% CI = 0.90-0.99, p = 0.03, N = 16,014), and the C-allele of NRG1 rs10503929 across all studies (OR = 0.89, 95% CI = 0.81-0.97, p = 0.01, N = 6844) and in Caucasian samples (OR = 0.89, 95% CI = 0.81-0.98, p = 0.01, N = 6414) were protective against schizophrenia. Our systematic meta-analysis is the most updated one for the association of DAO, DAOA, and NRG1 SNPs with schizophrenia.
Collapse
Affiliation(s)
- Vinita Jagannath
- Department of Child and Adolescent Psychiatry and Psychotherapy, University Hospital of Psychiatry Zurich, Centre for Child and Adolescent Psychiatry Research, University of Zurich, 5th Floor, Room K118, Wagistrasse 12, 8952, Schlieren, Switzerland
| | - Miriam Gerstenberg
- Department of Child and Adolescent Psychiatry and Psychotherapy, University Hospital of Psychiatry Zurich, Centre for Child and Adolescent Psychiatry Research, University of Zurich, 5th Floor, Room K118, Wagistrasse 12, 8952, Schlieren, Switzerland
| | - Christoph U Correll
- The Zucker Hillside Hospital, Psychiatry Research, Northwell Health, Glen Oaks, NY, USA.,Hofstra Northwell School of Medicine, Hempstead, NY, USA.,The Feinstein Institute for Medical Research, Manhasset, NY, USA
| | - Susanne Walitza
- Department of Child and Adolescent Psychiatry and Psychotherapy, University Hospital of Psychiatry Zurich, Centre for Child and Adolescent Psychiatry Research, University of Zurich, 5th Floor, Room K118, Wagistrasse 12, 8952, Schlieren, Switzerland.,Neuroscience Center Zurich, University of Zurich and ETH Zurich, Zurich, Switzerland.,Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland
| | - Edna Grünblatt
- Department of Child and Adolescent Psychiatry and Psychotherapy, University Hospital of Psychiatry Zurich, Centre for Child and Adolescent Psychiatry Research, University of Zurich, 5th Floor, Room K118, Wagistrasse 12, 8952, Schlieren, Switzerland. .,Neuroscience Center Zurich, University of Zurich and ETH Zurich, Zurich, Switzerland. .,Zurich Center for Integrative Human Physiology, University of Zurich, Zurich, Switzerland.
| |
Collapse
|
28
|
O'Tuathaigh CMP, Moran PM, Zhen XC, Waddington JL. Translating advances in the molecular basis of schizophrenia into novel cognitive treatment strategies. Br J Pharmacol 2017; 174:3173-3190. [PMID: 28667666 DOI: 10.1111/bph.13938] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/03/2017] [Revised: 06/07/2017] [Accepted: 06/12/2017] [Indexed: 02/06/2023] Open
Abstract
The presence and severity of cognitive symptoms, including working memory, executive dysfunction and attentional impairment, contributes materially to functional impairment in schizophrenia. Cognitive symptoms have proved to be resistant to both first- and second-generation antipsychotic drugs. Efforts to develop a consensus set of cognitive domains that are both disrupted in schizophrenia and are amenable to cross-species validation (e.g. the National Institute of Mental Health Cognitive Neuroscience Treatment Research to Improve Cognition in Schizophrenia and Research Domain Criteria initiatives) are an important step towards standardization of outcome measures that can be used in preclinical testing of new drugs. While causative genetic mutations have not been identified, new technologies have identified novel genes as well as hitherto candidate genes previously implicated in the pathophysiology of schizophrenia and/or mechanisms of antipsychotic efficacy. This review comprises a selective summary of these developments, particularly phenotypic data arising from preclinical genetic models for cognitive dysfunction in schizophrenia, with the aim of indicating potential new directions for pro-cognitive therapeutics. Linked Articles This article is part of a themed section on Pharmacology of Cognition: a Panacea for Neuropsychiatric Disease? To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.19/issuetoc.
Collapse
Affiliation(s)
- Colm M P O'Tuathaigh
- School of Medicine, University College Cork, Brookfield Health Sciences Complex, Cork, Ireland
| | - Paula M Moran
- School of Psychology, University of Nottingham, Nottingham, UK
| | - Xuechu C Zhen
- Jiangsu Key Laboratory of Translational Research & Therapy for Neuropsychiatric Disorders and Department of Pharmacology, College of Pharmaceutical Sciences, Soochow University, Suzhou, China
| | - John L Waddington
- Jiangsu Key Laboratory of Translational Research & Therapy for Neuropsychiatric Disorders and Department of Pharmacology, College of Pharmaceutical Sciences, Soochow University, Suzhou, China.,Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin 2, Ireland
| |
Collapse
|
29
|
Freyberg Z, Aslanoglou D, Shah R, Ballon JS. Intrinsic and Antipsychotic Drug-Induced Metabolic Dysfunction in Schizophrenia. Front Neurosci 2017; 11:432. [PMID: 28804444 PMCID: PMC5532378 DOI: 10.3389/fnins.2017.00432] [Citation(s) in RCA: 46] [Impact Index Per Article: 6.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2017] [Accepted: 07/13/2017] [Indexed: 12/12/2022] Open
Abstract
For decades, there have been observations demonstrating significant metabolic disturbances in people with schizophrenia including clinically relevant weight gain, hypertension, and disturbances in glucose and lipid homeostasis. Many of these findings pre-date the use of antipsychotic drugs (APDs) which on their own are also strongly associated with metabolic side effects. The combination of APD-induced metabolic changes and common adverse environmental factors associated with schizophrenia have made it difficult to determine the specific contributions of each to the overall metabolic picture. Data from drug-naïve patients, both from the pre-APD era and more recently, suggest that there may be an intrinsic metabolic risk associated with schizophrenia. Nevertheless, these findings remain controversial due to significant clinical variability in both psychiatric and metabolic symptoms throughout patients' disease courses. Here, we provide an extensive review of classic and more recent literature describing the metabolic phenotype associated with schizophrenia. We also suggest potential mechanistic links between signaling pathways associated with schizophrenia and metabolic dysfunction. We propose that, beyond its symptomatology in the central nervous system, schizophrenia is also characterized by pathophysiology in other organ systems directly related to metabolic control.
Collapse
Affiliation(s)
- Zachary Freyberg
- Department of Psychiatry, University of PittsburghPittsburgh, PA, United States
- Department of Cell Biology, University of PittsburghPittsburgh, PA, United States
| | - Despoina Aslanoglou
- Department of Psychiatry, University of PittsburghPittsburgh, PA, United States
| | - Ripal Shah
- Department of Psychiatry and Behavioral Sciences, Stanford UniversityStanford, CA, United States
| | - Jacob S. Ballon
- Department of Psychiatry and Behavioral Sciences, Stanford UniversityStanford, CA, United States
| |
Collapse
|
30
|
Uniting the neurodevelopmental and immunological hypotheses: Neuregulin 1 receptor ErbB and Toll-like receptor activation in first-episode schizophrenia. Sci Rep 2017. [PMID: 28646138 PMCID: PMC5482801 DOI: 10.1038/s41598-017-03736-3] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Current pathophysiological models of schizophrenia focus on neurodevelopmental and immunological mechanisms. We investigated a molecular pathway traditionally linked to the neurodevelopmental hypothesis (neuregulin 1 - ErbB), and pathogen-associated pattern recognition receptors associated with the immune hypothesis (Toll-like receptors, TLRs). We recruited 42 first-episode, drug-naïve patients with schizophrenia and 42 matched healthy control subjects. In monocytes TLR4/TLR5 and ErbB expressions were measured with flow-cytometry. Pro-inflammatory cytokines (IL-1β, IL-6, and TNF-α) and the anti-inflammatory cytokine IL-10 were determined following the stimulation of TLR4/TLR5 and ErbB. Results revealed increased TLR4/TLR5 and decreased ErbB4 expression in schizophrenia relative to the control subjects. The expression of ErbB2 and ErbB3 receptors was unaltered in schizophrenia. TLR4 stimulation resulted in lower pro-inflammatory cytokine production in schizophrenia compared to the control levels, whereas the stimulation of ErbB by neuregulin 1 led to higher pro-inflammatory cytokine levels in patients with schizophrenia relative to the control group. In healthy controls, ErbB activation was associated with a marked production of IL-10, which was dampened in schizophrenia. These results indicate that the stimulation of TLR4 and ErbB induces opposite pro-inflammatory cytokine responses in schizophrenia.
Collapse
|